Company intelligence / Profile preview
Novellus Therapeutics
- Ownership
- Private
- Development stage
- Other
01
Overview
Novellus Therapeutics developed next-generation engineered mesenchymal stem cell therapies using mRNA-based cell reprogramming and gene editing platforms, with most programs in preclinical development at the time of acquisition.
- Therapeutic areas
- Gastroenterology
- Modalities
- Cell therapyGene therapymRNA-based drugsInduced pluripotent stem cell derived therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Factor Bioscience (technology licensing)
Beyond the preview
Go deeper on Novellus Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novellus Therapeutics.